U.S. stocks on the move: Kodiak Sciences surged on September 28 due to DAYBREAK meeting targets and ophthalmic drug developments

Kodiak Sciences September 28 Surge Interpretation

Keywords: DAYBREAK milestone, ophthalmic drugs

1. On September 28, the company announced the results of the pivotal Phase 3 DAYBREAK trial. Both Zenkuda and KSI-501 met primary endpoints in patients with wet age-related macular degeneration; both demonstrated non-inferiority to aflibercept in one-year visual gains. The primary endpoint p-value for Zenkuda was 0.0007, for KSI-501 the visual primary endpoint p-value was 0.0036, and the p-value for the key anatomical secondary endpoint was less than 0.0001.

2. On September 28, Zenkuda showed rapid and sustained clinical efficacy. Under the stringent "dry-as-target" retreatment criteria, 54% of patients achieved six-month dosing durability at one year, and safety was consistent with the established safety profile of aflibercept. The company plans to submit a Biologics License Application for Zenkuda in the fourth quarter of 2026, covering five positive Phase 3 studies.

3. On September 28, the company is a biotechnology enterprise focused on retinal diseases and still in the pre-commercialization stage, advancing three late-stage clinical programs: Zenkuda, KSI-501, and KSI-101. Zenkuda and KSI-501 target the anti-VEGF market for retinal vascular diseases.

(Disclaimer: This content is summarized from publicly available information using AI technology and is for reference only. It does not constitute investment advice.)